Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Genetic Analysis AS. (10/5/21). "Press Release: Microbiome Dx Genetic Analysis Raises USD 6.8 M in IPO". Oslo.

Region Region Sweden
Organisation Organisation Genetic Analyis AS (GA)
Products Product GA-map® diagnostic platform
  Product 2 investment banking
Index term Index term Genetic Analysis (NO)–SEVERAL: investment, 202110 IPO at Swedish Spotlight Stock Market raising $6.8m
Person Person Hermansen, Ronny (Genetic Analysis 202110 CEO formerly Axis-Shield)

Closes up 50 % on first two days of trading as EU and US commercialisation drive of GA-map® platform begins

Microbiome DX company Genetic Analysis AS closed up 50% over the first two days of trading on the Swedish Spotlight Stock Market following completion of a share issue. The issue of units was oversubscribed to a total of approximately NOK 99 million, corresponding to a subscription ratio of approximately 165 percent, and the Company received approximately NOK 60 million before issue costs. Through the issue of units, approximately 1 200 new shareholders were added to GA including several leading Nordic and international private and institutional investors. The company now plans to use the funds to accelerate commercialisation of its proprietary GA-map® diagnostic platform for simultaneous analysis of gut microbiota.

CEO Ronny Hermansen comments:

”As research continues to demonstrate the strong links between intestinal health and wellbeing so does the need for accurate and reliable diagnosis. We believe that microbiome testing will be a game changer in healthcare moving forward. GA-map® provides the market with the standardised diagnostic platform needed to successfully develop microbiome-altering drugs that will benefit the vast number of patients suffering from bowel-related diseases such as IBS and IBD. We also see an on-going role for our tests for monitoring patient outcomes. I am delighted with the response to the listing and this new funding will now enable us to execute our growth plan to accelerate the commercialization of GA-map® in the EU and the US.”

For further information, please contact:
Ronny Hermansen, Chief Executive Officer

About Genetic Analysis:

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need of further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA holds 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering.

Record changed: 2021-10-22


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Fighting Customers 650x100px

» top